Global biopharmaceutical leader GSK PLC has entered into a definitive agreement to acquire efimosfermin, a promising ...

UnitedHealth Group Inc. on May 13 issued an update with two items of notable news, saying that its medical costs are likely ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Tucked inside Trump's drug-pricing executive order is an apparent threat to withdraw drugmakers' medicines if they do not ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Wall Street firms are trying to put private credit, equity and real estate into the hands of individual investors. Surging medical costs and regulatory changes hit UnitedHealth, but rivals such as ...

"It supports and provides free counselling and support services to adult survivors of childhood sexual abuse right across all the six counties of North Wales, and last year was the charity's fortieth ...

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...